Other Names
Rabbit Coagulation Factor VIII ELISA kit
FVIII; AHF; HEMA; F8B; F8C; Antihemophilic Globulin; Hemophilia A; Anti-Hemophilic Factor A; FVIII Procoagulant Component; F8 Protein
Research Area
Cardiovascular
Background
Factor VIII (FVIII) is an essential blood-clotting protein, also known as anti-hemophilic factor (AHF). In humans, factor VIII is encoded by the F8 gene. Defects in this gene result in hemophilia A, a recessive X-linked coagulation disorder. Factor VIII is produced in liver sinusoidal cells and endothelial cells outside of the liver throughout the body. This protein circulates in the bloodstream in an inactive form, bound to another molecule called von Willebrand factor, until an injury that damages blood vessels occurs. In response to injury, coagulation factor VIII is activated and separates from von Willebrand factor. The active protein (sometimes written as coagulation factor VIIIa) interacts with another coagulation factor called factor IX. This interaction sets off a chain of additional chemical reactions that form a blood clot. Factor VIII participates in blood coagulation; it is a cofactor for factor IXa which, in the presence of Ca2+ and phospholipids, forms a complex that converts factor X to the activated form Xa. The factor VIII gene produces two alternatively spliced transcripts. Transcript variant 1 encodes a large glycoprotein, isoform a, which circulates in plasma and associates with von Willebrand factor in a noncovalent complex. This protein undergoes multiple cleavage events. Transcript variant 2 encodes a putative small protein, isoform b, which consists primarily of the phospholipid binding domain of factor VIIIc. This binding domain is essential for coagulant activity. People with high levels of factor VIII are at increased risk for deep vein thrombosis and pulmonary embolism. Copper is a required cofactor for factor VIII and copper deficiency is known to decrease levels of factor VIII. There is a formulation as a medication that is on the WHO Model List of Essential Medicines, the most important medications needed in a basic health system.
Product Name |
F8 ELISA |
Species |
Rabbit |
Product Size |
96/48 Tests |
Concentration |
50-1000 ng/mL |
Sensitivity |
7.2 ng/mL |
Principle |
Competitive ELISA |
Sample Volume |
100 ul |
Assay Time |
90 minutes |
Platform |
Microplate Reader |
Conjugate |
HRP |
Detection Method |
Colorimetric |
Storage |
2-8°C |
|
For Research use only
Four parameter Logisticcurve regression
A = 1.73697 B = 0.73830 C = 3829.35241 D = -1.47167 r^2 = 0.99985 |
1. Protocols for ELISA
1) Direct ELISA
2) Direct ELISA Using Fluorescent Substrate
3) Indirect ELISA
4) Sandwich ELISA
2. Protocols for IHC ICC
1) Determining if the antibody binds only phosphorylated protein (WB or IHC)
2) Double immunofluorescence-sequential protocol
3) Double immunofluorescence-simultaneous protocol
4) Fixation and Permeabilization In IHC ICC
5) Glycol Methalacrylate Acrylic Resin Embedding For IHC
9) Immunohistochemistry (IHC-Fr) - Frozen Sections
3. Protocols for WB
4) S-100 Mitochondrial Fractionation
5) Stripping for Reprobing Western Blots
7) Western Blotting - A Beginner's Guide
8) Western Blotting of Phospho-Proteins
9) Western Blotting Using Antibodies Against Histone Proteins
4. Protocols for IP
2) Using IgM antibodies for IP
5. Protocols for FACS
1) Direct Staining Protocol (Cell Surface Staining)
3) Flow Cytometry Whole Blood Samples-Red Blood Cell Lysis
4) Indirect Staining Protocol (Cell Surface Staining)
6) Recommended Controls for FACS
6. Protocols for ELISPOT
1) ELISPOT